u/Peptide_Researcher_

I feel like everyone in this sub knows GHK-Cu for wound healing and skin, which is fair since that's where most of the early research is, but there's a decent body of work on nerve regeneration and antioxidant defense in neural tissue that doesn't come up nearly as much.

The mechanism that got me interested is pretty specific. In rat models, severed nerves placed in a collagen tube with GHK showed increased nerve outgrowth, more NGF and neurotrophin production, faster fiber regeneration, and higher Schwann cell proliferation compared to controls. Pickart's group also found GHK modulates roughly 600+ genes tied to neuron function specifically, on top of the broader few-thousand-gene footprint people usually cite (Pickart, Oxid Med Cell Longev, 2012, PMID 22666519).

What's less clear is how much of this translates past the animal/in vitro stage. GHK receptors are present in brain tissue and the mechanism is plausible, but there's basically no human neurological data yet, it's still early-stage compared to the collagen research which has decades behind it.

Full writeup with the gene expression data and antioxidant pathway stuff is here if anyone wants the deeper mechanism: https://spartanpeptides.com/blog/ghk-cu-neuroprotection-brain-nerve-regeneration-research/

Research use only, obviously. Anyone tracking whether there's actual human trial movement on the neuro side, or is it still purely preclinical at this point?

I keep seeing NAD+ described as "cellular energy currency" and leaving it there, which honestly undersells what's going on. There's a specific enzyme relationship here that doesn't get mentioned enough.

PARP1 is the protein that shows up first when DNA gets a double-strand break. It uses NAD+ directly as a substrate to build these poly-ADP-ribose chains that basically flag the damage site so the rest of the repair crew knows where to go. That part's pretty well known.

What's less talked about is that SIRT6, which is itself an NAD+-dependent enzyme, is what activates PARP1 in the first place. Mao et al. found that SIRT6 physically attaches to PARP1 and modifies it in a way that ramps up its repair activity under oxidative stress (Science, 2011, PMID 21680843). So you've got NAD+ needed twice in the same chain of events, once to power the enzyme that turns the system on, and again to fuel the repair enzyme itself.

That's probably part of why NAD+ decline gets treated as a bigger deal than a simple "less fuel in the tank" story. You're not just running low, you're losing the thing that activates the activator.

Wrote up the fuller mechanism (base excision repair, where SIRT6 fits, the whole chain) here if anyone wants to go deeper: https://spartanpeptides.com/blog/nad-plus-dna-repair/

Research use only obviously. Curious if anyone's seen good independent replication on the SIRT6-PARP1 interaction outside the original Mao paper, that's the piece I haven't dug into yet.

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a partial sequence found in human gastric juice. That origin matters more than it sounds — it's part of why the compound is unusually stable in acidic environments, which has made oral-route research an actual variable in a way it isn't for most peptides that get destroyed in the GI tract before doing anything.

The most consistently replicated finding in the literature is angiogenesis. BPC-157 upregulates VEGF expression, and in tendon-healing models it's been shown to accelerate fibroblast outgrowth from tendon explants and increase fibroblast migration and survival under oxidative stress (Chang et al., J Appl Physiol, 2011, PMID 21030672).

That mechanism — better blood supply to the injury site — is the throughline across most of what gets studied with this compound: tendon/ligament models, gut barrier and ulcer models, and muscle injury models all converge on the same angiogenic and growth-factor signaling.

Research-grade BPC-157 (≥98% HPLC-verified) is available via the BPC-157 research compound page — research use only, not for human consumption.

What's the application people here are researching it for most — tendon/joint models, or the gut-healing side?

A COA is only useful if you know what you're looking at. Saw too many people get a PDF and assume it's legit, so here's a quick field guide.

What a real COA should show:

1. Independent lab name + contact and not the vendor's own internal "QC." A third party you can actually look up.

2. Identity confirmation (mass spec / HPLC) proving the compound is what it says it is.

3. Purity percentage — the headline number, but meaningless without identity above it.

4. A batch/lot number that matches your vial. A generic COA not tied to your batch is a red flag.

5. A recent date. A two-year-old COA tells you nothing about the batch you just got.

Red flags: no lab name, no batch number, image-only with no traceable source, or purity claims with no identity test backing them.

Example of per-batch COAs done with a named independent lab if you want to see the format: https://spartanpeptides.com/quality-assurance/coa/

Anyone got other clean examples? Would be useful to build a reference for the sub.

>Genuinely curious where this community lands. There's a ton of marketing noise and it's hard to separate signal from hype.

My read, purely from the research literature:

• Overhyped: anything marketed as a "miracle" with thin or rodent-only data behind it.
• Underrated: the boring, well-studied peptides with replicated data that don't get hyped because they aren't new and shiny.

What I keep coming back to is third-party COA verification. Doesn't matter how good a compound is on paper if what's in the vial isn't what's on the label. I won't take a batch seriously without a recent independent purity/identity COA.

For reference, Spartan has per-batch independent lab results: https://spartanpeptides.com/quality-assurance/ (research library for cross-checking compounds: https://spartanpeptides.com/research/ )

Where do you all land? One compound you think is overrated, and one that deserves more attention?

>Been seeing a lot of confusion about BPC-157 protocols, so here's a clean summary of what the research literature actually shows on pharmacokinetics (research/educational only).

BPC-157 has a relatively short systemic half-life. The practical takeaway across most rodent-model literature is that consistency of administration tends to matter more than chasing a high single dose — a stable, frequent schedule keeps concentration in a more useful range than an occasional large bolus.

A few things worth knowing:

• Stability: It's reportedly stable in gastric environments, which is why oral research forms exist alongside injectable.
• Local vs systemic: A lot of the tendon/ligament data involves local effect, so site-of-administration comes up constantly.
• Reconstitution: Bacteriostatic water, kept cold, used within a reasonable window — standard handling for research peptides.

Decent mechanism write-up here if you want the deeper version: https://spartanpeptides.com/how-bpc-157-works/ and the broader compound reference: https://spartanpeptides.com/compounds/bpc-157/

Not medical advice, not for human consumption — strictly summarizing published research. What schedules have others seen referenced in the literature?

GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper) is one of the more studied tripeptides in the repair literature, and the scope of its activity is what makes it interesting. A 2012 analysis by Loren Pickart (PMID 22616637) reported that GHK-Cu modulates the expression of more than 4,000 human genes, shifting older-tissue expression patterns toward profiles seen in younger tissue. That is a wide footprint for a molecule the body already produces.

The endogenous angle is part of why researchers keep returning to it. Plasma GHK sits near 200 ng/mL around age 20 and falls to roughly 80 ng/mL by age 60. That decline tracks alongside the drop in tissue repair capacity that tends to come with age, which is the question a lot of the research is built around.

The most cited thread is collagen. Multiple studies document GHK-Cu stimulating fibroblast proliferation and upregulating collagen synthesis (Maquart et al., PMID 3998939, and PMID 10411201). A detailed breakdown of the collagen and wound-healing research is here: https://spartanpeptides.com/blog/ghk-cu-collagen-synthesis-wound-healing-tissue-repair-research/

Beyond collagen, the gene-expression work points at antioxidant defense pathways, anti-inflammatory signaling, and nervous-system repair genes, which is where the neuroprotection research has started to branch. There is also a smaller body of work on hair follicle cycling and dermal papilla activity.

Full compound overview with mechanism, receptor interactions, and a study index: https://spartanpeptides.com/compounds/ghk-cu/

For anyone sourcing material for in-vitro work, the 50mg research-grade GHK-Cu is here, third-party HPLC and mass-spec verified: https://spartanpeptides.com/products/ghk-cu-copper-peptide-50mg/ (the published COA shows 99.77% purity, expected mass 402.10 Da vs 402.14 found: https://spartanpeptides.com/quality-assurance/coa/ghk-cu/ )

More on the full product line and the lab program is at https://spartanpeptides.com

Curious what this community is most focused on with GHK-Cu right now. Is the neuroprotection side getting more attention, or is it still mostly the collagen and wound-healing work?

Why both HPLC and mass spec? HPLC tells you the percentage of target compound. Mass spec confirms what the compound actually is. A sample can be 99% pure and still be the wrong molecule if synthesis went sideways. Independent verification of both is the only thing that closes the loop. This is consistent with how the analytical chemistry literature handles peptide QC (Hoffmann & Janson 2012 PMID 22351040, on RP-HPLC peptide purity standards).

Why a third-party lab matters: in-house testing creates a conflict of interest. The lab paid by the vendor has no incentive to inflate purity numbers. MZ Biolabs has no ownership, financial, or operational relationship with Spartan beyond paying for analytical services. You can verify them independently at mzbiolabs.com.

Full quality program writeup with the testing methodology, batch protocol, and the FAQ section: https://spartanpeptides.com/quality-assurance/

Browse every published COA: https://spartanpeptides.com/quality-assurance/coa/

If you're a researcher comparing suppliers, the questions to ask are: who signed the COA, what methods were used, what was the analysis date, and is the document the original or a summary. Those four answers separate real verification from marketing copy.

For anyone running recovery research, the Wolverine Stack (BPC-157 + TB-500 combo) is one of the most-cited pairs in the published lit. BPC-157 carries the angiogenesis side, TB-500 covers the cellular migration and actin work. Together they hit the two main axes of tissue repair biology.

Memorial Day sale brings the bundle down meaningfully through Sunday. Full mechanism breakdown is on the product page if you want to read the synergy rationale.

Code MEMORIAL25 at checkout. Link: spartanpeptides.com/products/wolverine-bpc-157-tb-500

Research use only.

Spartan Peptides is running 25% off everything on the site through this Sunday.

We also just rolled out a new Research Stacks section that bundles a few popular combos (Wolverine, Longevity Panel, Cognitive Stack, and a couple more), with full mechanism writeups and PubMed citations on each product page.

Code is MEMORIAL25 at checkout. Site is spartanpeptides.com if you want to take a look.

Happy holiday weekend.

BPC-157 is probably the most-asked-about peptide in recovery research threads. Here's a structured research-context overview of what the literature actually shows, anchored to recent guides we've put together.

What BPC-157 is

BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide originally isolated from human gastric juice. It's a fragment of a larger gastric protein. The name comes from its observed protective effect on gastrointestinal tissue in early research.

The research mechanisms (preclinical models)

The literature points to multiple parallel pathways, which is part of why BPC-157 research has covered such a wide range of applications:

• Angiogenesis upregulation: VEGFR2 receptor activation, accelerated new blood vessel formation in injury sites
• Nitric oxide system modulation: balances NO signaling, which underlies its observed vascular and gastric effects
• Fibroblast migration acceleration: speeds up connective tissue repair in tendon/ligament research models
• Gastric cytoprotection: protects the gastric mucosa from NSAIDs, alcohol, and corticosteroid damage in animal models

What the research is actually showing

• Accelerated tendon-to-bone healing in rat Achilles transection models
• Reduced gut inflammation markers in IBD-equivalent rodent models
• Protective effect against NSAID-induced gastric ulceration
• Some cardioprotective signals in ischemia-reperfusion injury studies
• Faster wound closure in dermal punch biopsy models

What the research is NOT showing yet

• Large-scale human RCT data, there isn't any meaningful trial data yet
• Long-term safety profile in humans, unknown
• Optimal dosing for human therapeutic use, also unknown
• FDA approval, none

This is why BPC-157 lives squarely in the research-only category despite all the anecdotal noise around it.

Common research dosing observations (preclinical, NOT human guidance)

• 250-500 mcg per day in animal models
• Typical research panels: 4-6 weeks duration
• Both injection and oral routes studied (oral has lower bioavailability but still shows gastric protective effects)

Caveats worth saying every time

• Not FDA approved for any human therapeutic use
• All evidence is preclinical
• Lab-to-lab purity variability is real, especially for compounds in heavy demand
• HPLC verification matters

Deeper reading:

• BPC-157 gut cytoprotection research guide: https://spartanpeptides.com/blog/bpc-157-gut-health-gastric-cytoprotection-research/
• BPC-157 preclinical study findings: https://spartanpeptides.com/blog/bpc-157-research-results-2026-preclinical-studies-tissue-repair/
• Wolverine Stack (BPC-157 + TB-500) protocol: https://spartanpeptides.com/blog/wolverine-stack-dosage-guide-bpc-157-tb-500-research-protocol-2026/

Product: https://spartanpeptides.com/products/bpc-157/

Happy to dig into specific tendon studies or gastric protection mechanisms if anyone has questions.

Tesamorelin gets brought up a lot in GH-axis discussions but it works very differently from the GHRP-class peptides. Here's the research-context breakdown for anyone digging into the literature.

What Tesamorelin is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the natural 44-amino-acid hormone that signals the pituitary to release GH. The modification is a hexenoic acid attached to the N-terminus, which protects the peptide from rapid degradation by DPP-4. The result is a longer-acting GHRH signal compared to native GHRH (which has a half-life under 10 minutes).

How it differs from CJC-1295 and from Ipamorelin

This is the comparison that gets confused most often:

• Tesamorelin: stabilized GHRH analog, intermediate half-life (~30 minutes), no DAC modification
• CJC-1295 (with DAC): GHRH analog with extended albumin-binding half-life (days)
• CJC-1295 (without DAC, sometimes called "Mod GRF 1-29"): same backbone, shorter half-life
• Ipamorelin: NOT a GHRH analog. It's a ghrelin receptor agonist. Different pathway entirely.

So Tesamorelin and CJC-1295 are cousins (both GHRH analogs). Ipamorelin is from a different family.

Key research observations

• Sustained pulsatile GH release in preclinical models without the receptor-desensitization seen with continuous GH dosing
• Most-studied research application: visceral adipose tissue reduction in HIV-lipodystrophy clinical research models (this is the only FDA-approved indication, marketed as Egrifta in that specific population)
• Research in non-clinical contexts: lean mass preservation, lipid metabolism markers, IGF-1 elevation
• Does NOT independently affect ghrelin, cortisol, or prolactin pathways

Research dosing context

• Typical research doses observed in literature: 1-2 mg subcutaneously per day
• Half-life intermediate (~30 min systemic, but downstream GH effects last several hours)
• Often run in 12-week research panels in animal/cell models

Caveats

• Approved for one narrow clinical indication only
• All other research applications are exploratory
• Not for human consumption outside that specific clinical use
• Spartan compounds are research-grade only

Deeper reading:

• Tesamorelin complete 2026 research guide: https://spartanpeptides.com/blog/tesamorelin-complete-2026-research-guide-ghrh-lean-mass/
• CJC-1295 + Ipamorelin guide (the more common stack comparison): https://spartanpeptides.com/blog/cjc-1295-ipamorelin-complete-2026-research-guide/
• Peptides for hormone optimization research overview: https://spartanpeptides.com/blog/hormone-optimization-peptides/

Product: https://spartanpeptides.com/products/tesamorelin-5-mg/

If anyone wants to go deeper on the Tesamorelin vs CJC-1295 distinction, happy to walk through it.

The CJC-1295 + Ipamorelin combination is one of the most asked-about peptide stacks in research circles, so here's a structured rundown of why these two get paired and what the literature actually says.

Why the pairing exists

CJC-1295 and Ipamorelin act on different points of the same pathway, which makes the combination synergistic rather than redundant.

• CJC-1295 is a GHRH (growth hormone-releasing hormone) analog. It stimulates the anterior pituitary to release GH by extending the natural GHRH signal. The DAC (Drug Affinity Complex) variant has an extended half-life via albumin binding.
• Ipamorelin is a selective ghrelin receptor agonist. It triggers GH release through a different receptor pathway and is known for being highly selective: minimal cortisol or prolactin elevation in research models, which is what separates it from older GHRPs like GHRP-6.

Stacked together, you get GHRH amplification + ghrelin-pathway stimulation. The result in preclinical research models is a stronger, more pulsatile GH release than either compound alone produces.

Common research observations

• Pulsatile GH release pattern that more closely mimics endogenous secretion
• Minimal off-target hormonal effects (cortisol, prolactin) compared to older GH secretagogue stacks
• Synergistic IGF-1 elevation seen in animal models when both are present vs. either alone
• Half-life mismatch: Ipamorelin clears in ~2 hours; CJC-1295 with DAC persists for days. This is intentional, the short pulse from Ipamorelin layers on top of the steady CJC baseline.

Research dosing context (preclinical, not human therapeutic guidance)

• CJC-1295: typically 100-300 mcg per dose in research panels
• Ipamorelin: typically 200-300 mcg per dose
• Combined research blends often dose 5/5mg per vial reconstituted

Caveats worth saying out loud

• Not FDA approved for human use
• All research is preclinical (rodent models, in vitro studies)
• GH secretagogue research has been around since the 1990s but human trial data remains limited
• Lab-to-lab variability in peptide purity is real; HPLC verification matters

Deeper reading:

• CJC-1295 + Ipamorelin complete research guide: https://spartanpeptides.com/blog/cjc-1295-ipamorelin-complete-2026-research-guide/
• Tesamorelin (another GHRH analog) research guide: https://spartanpeptides.com/blog/tesamorelin-complete-2026-research-guide-ghrh-lean-mass/
• Ipamorelin selective secretagogue guide: https://spartanpeptides.com/blog/ipamorelin-selective-gh-secretagogue-research-guide/

Product: https://spartanpeptides.com/products/cjc-ipa-10-mg-blend/

Happy to discuss specific studies if anyone has questions on dose timing or pulse architecture.

The "Wolverine Stack" question comes up constantly in recovery threads, so here's a research-context overview of why BPC-157 and TB-500 keep showing up together in healing protocols.

Why the pairing

The reason these two are stacked is that they target healing through different mechanisms. Combining them gives you broader tissue coverage than either one alone.

• BPC-157 (Body Protection Compound, 15 amino acids) drives angiogenesis, accelerates tendon-to-bone healing, and protects the gut lining. Its strongest preclinical signal is in soft-tissue and ligament repair.

• TB-500 (synthetic Thymosin Beta-4 fragment) promotes cell migration, reduces inflammation, and aids muscle regeneration. Its strongest signal is in systemic recovery and muscle tissue.

In research models the two compounds work on overlapping but distinct pathways, so the combined effect addresses connective tissue repair plus systemic muscle recovery in parallel.

Mechanisms (preclinical observations)

• BPC-157, upregulates VEGFR2 and stimulates new blood vessel formation, accelerates fibroblast migration, modulates the nitric oxide system

• TB-500, binds G-actin to control cytoskeletal organization, downregulates inflammatory cytokines, supports stem cell migration to injury sites

The angiogenesis from BPC-157 plus the cell migration from TB-500 creates a research-observed synergy, not just additive effects.

Common research dosing protocols (preclinical)

Standard ranges seen in the literature for parallel research panels:

• BPC-157, typically 250 to 500 mcg per dose, daily for 4 to 6 weeks

• TB-500, typically 2 to 5 mg per dose, twice weekly for 4 to 6 weeks

Higher doses on TB-500 reflect its longer half-life. Standard caveat: these are research-context dosing observations, not human therapeutic recommendations.

What the research is actually showing

• Faster tendon healing in rat Achilles transection models

• Reduced muscle damage markers post-exercise stress in animal panels

• Improved gut barrier function (BPC-157 specifically)

• Accelerated wound closure in dermal punch biopsy models

• Cardioprotective signals in ischemia-reperfusion injury studies

What the research is not showing yet is large-scale human RCT data, which is why all of this stays in the research-only category.

Caveats worth saying out loud

• Both compounds are research-grade only. Not FDA-approved for human therapy.

• Most data comes from rodent models. Human pharmacokinetics for these specific peptides remain understudied.

• Lab-to-lab variability in peptide purity is real. HPLC verification matters.

• If you're running a research panel, follow institutional protocols.

Deeper reading:

• Wolverine Stack full dosage and protocol guide: https://spartanpeptides.com/blog/wolverine-stack-dosage-guide-bpc-157-tb-500-research-protocol-2026/

• BPC-157 research results, what preclinical studies show: https://spartanpeptides.com/blog/bpc-157-research-results-2026-preclinical-studies-tissue-repair/

• Complete guide to healing and recovery peptides: https://spartanpeptides.com/blog/complete-guide-to-healing-recovery-peptides/

Happy to dig into specific studies if anyone wants to discuss particular protocols or mechanisms.

Putting together a research roundup on Selank since it gets asked about a lot in peptide threads. Sharing the key points and linking to the deep dives we put together for anyone digging into the literature.

What Selank is

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed in Russia in the 1990s. It's a stable analog of the immune peptide tuftsin, with the addition of a Pro-Gly-Pro tail that extends its biological half-life. Originally studied for anxiolytic effects, the research has since expanded into cognitive performance, immune modulation, and neuroprotection.

Key research observations

• Acts on multiple neurotransmitter systems including GABA, serotonin, dopamine, and norepinephrine

• Upregulates BDNF and NGF expression in animal models

• Anxiolytic effect is comparable to benzodiazepines in some preclinical studies, without sedation, dependence, or tolerance build-up

• Crosses the blood-brain barrier through saturable transport

• Half-life is short systemically but observed neurochemical effects last up to 24 hours

Selank vs Semax (since people always ask)

Both are Russian-developed heptapeptides, but they target different problems:

• Selank, anxiolytic-leaning, GABAergic modulation, mild cognitive support

• Semax, neuroprotective and nootropic-leaning, BDNF and dopamine focus, cognitive enhancement primary

In research designs they're sometimes paired, with Selank addressing anxiety substrate and Semax handling the cognitive performance side.

Common research stacks observed in the literature

• Selank + Semax for combined anxiolytic-cognitive panels

• Selank + DSIP or Pinealon when sleep architecture is a co-variable

• Standalone Selank for isolated GABA-system studies

Standard caveats

All of this is research-context. None of it is medical advice. Selank is sold for laboratory use only and has not been FDA-approved for human consumption. If you're researching it, follow your institutional protocols and source from suppliers who provide HPLC verification.

Deeper reading we put together:

• Selank full research guide, mechanism, half-life, stacks: https://spartanpeptides.com/blog/selank-anti-anxiety-neuropeptide-research-guide/

• Semax + Selank combined cognitive/anxiolytic research: https://spartanpeptides.com/blog/enhancing-mental-performance-with-semax-and-selank/

• Pinealon neuroprotective tripeptide guide (sometimes paired with Selank): https://spartanpeptides.com/blog/pinealon-neuroprotective-tripeptide-research-guide/

Happy to discuss specific studies or research questions if anyone has them.